(3) BCL2, MCL1: Basic research has shown that venetoclax, a BCL2 inhibitor, selectively acts on BCL2, and MCL1 compensatory upregulation leads to its resistance, which is particularly evident in relapsed/refractory AML (R/R AML) patients. Here, BCL2 is linked to acute myeloid leukemia.